


**REMARKS**

In response to the restriction requirement, Applicants provisionally elect with traverse the invention set forth in Group II, claims 9-22, drawn to the compounds, compositions, and methods of use of the compounds of formula I where A-B is  $\text{NR}^5\text{-SO}_2$  and where W is  $(\text{CH}_2)_2$  or  $\text{CH=CH}$ .

Regarding the election of a single species, Applicants elect the compound of example 33:

6-Ethyl-*N*-{(1*S*,2*R*)-2-hydroxy-1-(phenylmethyl)-3-[(3,3,3-trifluoropropyl)amino]propyl}-1-methyl-1,3,4,6-tetrahydro[1,2]thiazepino[5,4,3-*cd*]indole-8-carboxamide 2,2-dioxide


depicted as:



This compound is encompassed by claims 9-18 and 20-22.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

  
Bonnie L. Deppenbrock  
Attorney for Applicant  
Registration No. 28,209

Date: 25 July 2008  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-1577  
Facsimile: 919-483-7988